The results demonstrate that recipients tolerated the higher dose of transplanted hepatocytes, affirming the effectiveness of our gene-editing approach in rescuing Fah−/− mice from liver and renal dysfunction, as well as hypoglycemia. The gene discussed is FAH; the disease is Abnormal renal physiology.